- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06081946
Investigação dos efeitos da fragmentação do sono na coceira e na sensibilidade à dor
Investigação dos efeitos das provocações do sono na coceira e na sensibilidade à dor
In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep fragmentation on itch:
- To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.
- To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.
- To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep fragmentation.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals. Furthermore, there is a lack of efficient treatment options for chronic itch.
Poor sleep is a common companion of itch and is often reported by patients with chronic itch. Poor sleep is often characterized by nightly awakenings and troubles falling asleep. This is a significant problem as poor sleep in general is associated with lowered quality of life. While previous research has already established the negative impact of itch on sleep, it is yet to be studied whether the opposite tendency might be true as well. Knowledge about patients with chronic pain has shown that poor sleep can increase the sensitivity to pain and inflammation, and this tendency can also be observed in healthy participants after experimental sleep provocations.
Therefore, the investigators wish to investigate how sleep provocations affect markers of itch in healthy participants.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Aalborg, Dinamarca, 9620
- Aalborg University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy men and women
- 18-60 years
- Speak and understand English
- Access to a smartphone during the experimental nights
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.)
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines and pain killers.
- Skin diseases
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain and itch
- Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)
- Lack of ability to cooperate
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sleep fragmentation
This subproject will be conducted in two sessions separated by three nights of sleep fragmentation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted. |
Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessment of pain
Prazo: Day 1: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'. |
Day 1: 1 minute after every itch inductions
|
|
Assessment of pain
Prazo: Day 2: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'. |
Day 2: 1 minute after every itch inductions
|
|
Assessment of itch
Prazo: Day 1: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'. |
Day 1: 1 minute after every itch inductions
|
|
Assessment of itch
Prazo: Day 2: 1 minute after every itch inductions
|
Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'. |
Day 2: 1 minute after every itch inductions
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Touch Pleasantness (TP)
Prazo: Day 2: 10 minutes after every itch inductions
|
Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN. The stimulation consists of three strokes (2 cm in length) over the treated/control areas. The strokes will be applied perpendicularly to the skin and the subject will rate the sensation induced by the brush on a NRS scale labeled "very unpleasant" and "very pleasant" at the extremity and "neutral" at the center. |
Day 2: 10 minutes after every itch inductions
|
|
Cold Detection Thresholds (CDT) and heat (HPT) detection
Prazo: Day 1: 10 minutes after every itch inductions
|
Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm |
Day 1: 10 minutes after every itch inductions
|
|
Cold Detection Thresholds (CDT) and heat (HPT) detection
Prazo: Day 2: 10 minutes after every itch inductions
|
Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm |
Day 2: 10 minutes after every itch inductions
|
|
Cold Detection Thresholds (CDT) and heat (HPT) pain thresholds
Prazo: Day 1: 10 minutes after every itch inductions
|
Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm |
Day 1: 10 minutes after every itch inductions
|
|
Cold Detection Thresholds (CDT) and heat (HPT) pain thresholds
Prazo: Day 2: 10 minutes after every itch inductions
|
Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm |
Day 2: 10 minutes after every itch inductions
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Prazo: Day 1: 10 minutes after every itch inductions
|
The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will rate the pain to three suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C). |
Day 1: 10 minutes after every itch inductions
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Prazo: Day 2: 10 minutes after every itch inductions
|
The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will rate the pain to three suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C). |
Day 2: 10 minutes after every itch inductions
|
|
Deep-tissue Pain Sensitivity Measurements
Prazo: Day 1: 10 minutes after every itch inductions
|
Deep-tissue pain sensitivity will be evaluated by cuff pressure stimuli using a computer-controlled cuff algometer (Cortex Technology and Aalborg University, Denmark) including a 13-cm wide tourniquet cuff (VBM, Sulz, Germany) and an electronic visual analog scale (VAS) (Aalborg University, Denmark) for recording of the pain intensity. |
Day 1: 10 minutes after every itch inductions
|
|
Deep-tissue Pain Sensitivity Measurements
Prazo: Day 2: 10 minutes after every itch inductions
|
Deep-tissue pain sensitivity will be evaluated by cuff pressure stimuli using a computer-controlled cuff algometer (Cortex Technology and Aalborg University, Denmark) including a 13-cm wide tourniquet cuff (VBM, Sulz, Germany) and an electronic visual analog scale (VAS) (Aalborg University, Denmark) for recording of the pain intensity. |
Day 2: 10 minutes after every itch inductions
|
|
Pressure Detection and Tolerance Threshold
Prazo: Day 1: 10 minutes after every itch inductions
|
The pressure will be increased by 1 kPa/s and the subject will be instructed to rate the pain intensity continuously on the electronic VAS until the tolerance level is reached. |
Day 1: 10 minutes after every itch inductions
|
|
Pressure Detection and Tolerance Threshold
Prazo: Day 2: 10 minutes after every itch inductions
|
The pressure will be increased by 1 kPa/s and the subject will be instructed to rate the pain intensity continuously on the electronic VAS until the tolerance level is reached. |
Day 2: 10 minutes after every itch inductions
|
|
Temporal Summation of Pain - TSP
Prazo: Day 1: 10 minutes after every itch inductions
|
A total of 10 repeated mechanical pressure stimuli at the PTT level will be delivered at 0.5 Hz (1 s stimulus duration and 1 s interval between stimuli) to the lower leg. A constant pressure of 5 kPa will be applied between the individual pressure stimuli to avoid movement of the cuff. During the 10 repeated stimuli, the subject will continuously rate the pain intensity on a 10 cm continuous VAS. |
Day 1: 10 minutes after every itch inductions
|
|
Temporal Summation of Pain - TSP
Prazo: Day 2: 10 minutes after every itch inductions
|
A total of 10 repeated mechanical pressure stimuli at the PTT level will be delivered at 0.5 Hz (1 s stimulus duration and 1 s interval between stimuli) to the lower leg. A constant pressure of 5 kPa will be applied between the individual pressure stimuli to avoid movement of the cuff. During the 10 repeated stimuli, the subject will continuously rate the pain intensity on a 10 cm continuous VAS. |
Day 2: 10 minutes after every itch inductions
|
|
Microvascular reactivity
Prazo: Day 1: 10 minutes after every itch inductions
|
The evoked cutaneous inflammation (quantified by superficial blood perfusion) will be measured by full-field laser perfusion imaging. |
Day 1: 10 minutes after every itch inductions
|
|
Microvascular reactivity
Prazo: Day 2: 10 minutes after every itch inductions
|
The evoked cutaneous inflammation (quantified by superficial blood perfusion) will be measured by full-field laser perfusion imaging. |
Day 2: 10 minutes after every itch inductions
|
|
Touch Pleasantness (TP)
Prazo: Day 1: 10 minutes after every itch inductions
|
Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN. The stimulation consists of three strokes (2 cm in length) over the treated/control areas. The strokes will be applied perpendicularly to the skin and the subject will rate the sensation induced by the brush on a NRS scale labeled "very unpleasant" and "very pleasant" at the extremity and "neutral" at the center. |
Day 1: 10 minutes after every itch inductions
|
|
Mechanically evoked itch (MEI), intensity approach
Prazo: Day 1: 10 minutes after every itch inductions
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). This stimulator is moved in intervals of 0.5 cm outside the area of itch provocation. |
Day 1: 10 minutes after every itch inductions
|
|
Mechanically evoked itch (MEI), intensity approach
Prazo: Day 2: 10 minutes after every itch inductions
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). This stimulator is moved in intervals of 0.5 cm outside the area of itch provocation. |
Day 2: 10 minutes after every itch inductions
|
|
Mechanically evoked itch, spatial approach
Prazo: Day 1: 10 minutes after every itch inductions
|
The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms) |
Day 1: 10 minutes after every itch inductions
|
|
Mechanically evoked itch, spatial approach
Prazo: Day 2: 10 minutes after every itch inductions
|
The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms) |
Day 2: 10 minutes after every itch inductions
|
|
Mechanical Pain Thresholds (MPT)
Prazo: Day 1: 10 minutes after every itch inductions
|
This test is conducted using a pinprick set (Aalborg University, Aalborg). The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Day 1: 10 minutes after every itch inductions
|
|
Mechanical Pain Thresholds (MPT)
Prazo: Day 2: 10 minutes after every itch inductions
|
This test is conducted using a pinprick set (Aalborg University, Aalborg). The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Day 2: 10 minutes after every itch inductions
|
|
Mechanical Pain Sensitivity (MPS), intensity approach
Prazo: Day 1: 10 minutes after every itch inductions
|
This test is conducted with the same pinprick set used to test the MPT. Starting with the lightest, each stimulator is applied at a rate of 2 s on, 2 s off in an ascending order, and the subject will be asked to give a pain rating for each stimulus on a scale from 0-10 (where 0 indicates ''no pain'', and 10 indicates the ''worst imaginable pain''). |
Day 1: 10 minutes after every itch inductions
|
|
Mechanical Pain Sensitivity (MPS), intensity approach
Prazo: Day 2: 10 minutes after every itch inductions
|
This test is conducted with the same pinprick set used to test the MPT. Starting with the lightest, each stimulator is applied at a rate of 2 s on, 2 s off in an ascending order, and the subject will be asked to give a pain rating for each stimulus on a scale from 0-10 (where 0 indicates ''no pain'', and 10 indicates the ''worst imaginable pain''). |
Day 2: 10 minutes after every itch inductions
|
|
Conditioned Pain Modulation - CPM
Prazo: Day 1: 10 minutes after every itch inductions
|
The concept of CPM is that a tonic painful stimulus (conditioning stimulus) will inhibit pain evoked simultaneously from another site (test stimulus). The painful conditioned stimulus will be applied simultaneously with the assessment stimulus. The conditioned stimulus will be terminated right after the subject presses the stop button. CPM will be defined as the difference between stimulus during and before the conditioned pain (i.e., "during" minus "before"). |
Day 1: 10 minutes after every itch inductions
|
|
Conditioned Pain Modulation - CPM
Prazo: Day 2: 10 minutes after every itch inductions
|
The concept of CPM is that a tonic painful stimulus (conditioning stimulus) will inhibit pain evoked simultaneously from another site (test stimulus). The painful conditioned stimulus will be applied simultaneously with the assessment stimulus. The conditioned stimulus will be terminated right after the subject presses the stop button. CPM will be defined as the difference between stimulus during and before the conditioned pain (i.e., "during" minus "before"). |
Day 2: 10 minutes after every itch inductions
|
|
The Itch Catastrophizing Scale
Prazo: Day 1
|
The itch catastrophizing scale is a modified version of the pain catastrophizing scale (PCS), which is a validated questionnaire measuring pain-related thoughts and feelings. The questionnaire consists of 13 items measuring itch-related thoughts and feelings. Each item is rated on a 4-point scale ranging from zero to four, corresponding to thinking/feeling that way during itch 'not at all' and 'very much', respectively. |
Day 1
|
|
The Itch Catastrophizing Scale
Prazo: Day 2
|
The itch catastrophizing scale is a modified version of the pain catastrophizing scale (PCS), which is a validated questionnaire measuring pain-related thoughts and feelings. The questionnaire consists of 13 items measuring itch-related thoughts and feelings. Each item is rated on a 4-point scale ranging from zero to four, corresponding to thinking/feeling that way during itch 'not at all' and 'very much', respectively. |
Day 2
|
|
The Pittsburg Sleep Quality Index (PSQI)
Prazo: Day 1
|
The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The seven component scores can be summarized in a global score ranging from zero to 21 with higher scores reflecting a worse overall quality of sleep. |
Day 1
|
|
The Pittsburg Sleep Quality Index (PSQI)
Prazo: Day 2
|
The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The seven component scores can be summarized in a global score ranging from zero to 21 with higher scores reflecting a worse overall quality of sleep. |
Day 2
|
|
The Hospital Anxiety and Depression Scale (HADS)
Prazo: Day 1
|
The HADS consists of 14 items with two 7-item subscales measuring anxiety and depression symptoms, respectively. Each item is scored on a 4-point scale with zero to three with each subscale ranging from zero to 21. Within both subscales, the scoring is grouped into either normal (0-7), borderline abnormal (8-10), and abnormal (11-21). |
Day 1
|
|
The Hospital Anxiety and Depression Scale (HADS)
Prazo: Day 2
|
The HADS consists of 14 items with two 7-item subscales measuring anxiety and depression symptoms, respectively. Each item is scored on a 4-point scale with zero to three with each subscale ranging from zero to 21. Within both subscales, the scoring is grouped into either normal (0-7), borderline abnormal (8-10), and abnormal (11-21). |
Day 2
|
|
Positive and Negative Affective Schedule
Prazo: Day 1
|
This 20-item instrument is a psychometric self-report test to assess affect (10 items for positive affect and 10 items for negative affect) and validated for the use in adolescents and adults. |
Day 1
|
|
Positive and Negative Affective Schedule
Prazo: Day 2
|
This 20-item instrument is a psychometric self-report test to assess affect (10 items for positive affect and 10 items for negative affect) and validated for the use in adolescents and adults. |
Day 2
|
|
Blood Sampling for C-Reactive Protein Analysis
Prazo: Day 1
|
Whole blood samples will be collected from the antecubital vein using a vacutainer blood collection device (S-Monovette, Sarstedt) with a 21-gauge needle. |
Day 1
|
|
Blood Sampling for C-Reactive Protein Analysis
Prazo: Day 2
|
Whole blood samples will be collected from the antecubital vein using a vacutainer blood collection device (S-Monovette, Sarstedt) with a 21-gauge needle. |
Day 2
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Distúrbios do Sono Vigília
- Dissônias
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Privação de sono
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Azoles
- Fatores biológicos
- Imidazoles
- Aminas
- Etilaminas
- AutoCoids
- Mediadores de inflamação
- Monoaminas biogênicas
- Aminas biogênicas
- Histamina
Outros números de identificação do estudo
- N-20230028
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .